PMID- 14720383
OWN - NLM
STAT- MEDLINE
DCOM- 20040430
LR  - 20201113
VI  - 23
IP  - 1
DP  - 2004 Jan
TI  - [Expression of p73 and PTEN in laryngeal squamous cell carcinoma and their 
      clinical significance].
PG  - 90-4
AB  - BACKGROUND & OBJECTIVE: There are few ideal predictors used to evaluate the 
      prognosis of laryngeal squamous cell carcinoma (LSCC). This study was designed to 
      investigate the expression of p73 and PTEN (phosphates and tension homolog 
      deleted on chromosome ten) and their association with clinical, histologic 
      characteristics and prognosis in LSCC. METHODS: p73 protein and PTEN protein were 
      examined by using immunochistochemical SABC staining method in 65 cases of LSCC 
      and in 23 cases of para-tumor tissues. RESULTS: p73 protein and PTEN protein in 
      LSCC showed positive expression of about 58.5% (38/65) and 49.2% (32/65), 
      compared to para-tumor tissues of about 17.4% (4/23) and 95.7% (22/23) with 
      statistical significance (P< 0.05). p73 protein positive expression showed 
      stronger in stage III-IV of LSCC than that in stage I-II (P< 0.05); it more often 
      appeared in recurrent cases than in primary cases (P< 0.05). And p73 protein 
      positive expression with distant metastasis was stronger than that in LSCC 
      without distant metastasis (P< 0.05). PTEN protein positive expression was 
      stronger in stage I-II of LSCC than that in stage III-IV (P< 0.05); PTEN protein 
      positive expression appears less frequently in poor differentiation of LSCC, 
      compared to well/moderate differentiation (P< 0.05); PTEN positive expression in 
      cases with cervical lymph node metastasis and distant metastasis was lower than 
      that in those without metastasis (P< 0.05). PTEN expression showed significantly 
      stronger in the patients whose survival time over 5 years (66.7%) than in the 
      patients whose survival time was less than 5 years (27.3%) (P< 0.05). CONCLUSION: 
      PTEN positive expression may be useful for predicting the prognosis of LSCC.
FAU - Tian, Shen-Zhi
AU  - Tian SZ
AD  - Department of Otolaryngology, Zhongnan Hospital of Wuhan University, Wuhan, 
      Hubei, 430071, P.R.China.
FAU - Jiang, Xiao-Qing
AU  - Jiang XQ
FAU - Chi, Hai-Chao
AU  - Chi HC
FAU - Zhou, Xu-Hong
AU  - Zhou XH
LA  - chi
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Ai Zheng
JT  - Ai zheng = Aizheng = Chinese journal of cancer
JID - 9424852
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Nuclear Proteins)
RN  - 0 (TP73 protein, human)
RN  - 0 (Tumor Protein p73)
RN  - 0 (Tumor Suppressor Proteins)
RN  - EC 3.1.3.2 (Phosphoric Monoester Hydrolases)
RN  - EC 3.1.3.67 (PTEN Phosphohydrolase)
RN  - EC 3.1.3.67 (PTEN protein, human)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Carcinoma, Squamous Cell/*chemistry/pathology
MH  - DNA-Binding Proteins/*analysis/genetics
MH  - Female
MH  - Genes, Tumor Suppressor
MH  - Humans
MH  - Immunohistochemistry
MH  - Laryngeal Neoplasms/*chemistry/pathology
MH  - Male
MH  - Middle Aged
MH  - Nuclear Proteins/*analysis/genetics
MH  - PTEN Phosphohydrolase
MH  - Phosphoric Monoester Hydrolases/*analysis/genetics
MH  - Tumor Protein p73
MH  - Tumor Suppressor Proteins/*analysis/genetics
EDAT- 2004/01/15 05:00
MHDA- 2004/05/01 05:00
CRDT- 2004/01/15 05:00
PHST- 2004/01/15 05:00 [pubmed]
PHST- 2004/05/01 05:00 [medline]
PHST- 2004/01/15 05:00 [entrez]
AID - 1000467X2004010090 [pii]
PST - ppublish
SO  - Ai Zheng. 2004 Jan;23(1):90-4.